{"contentid": 488201, "importid": NaN, "name": "Self-injectable antibody wins multiple sclerosis nod in Europe", "introduction": "Danish cancer specialist Genmab has announced the granting of European approval to its development partner, Novartis, for Kesimpta (ofatumumab).", "content": "<p>Danish cancer specialist Genmab (Nasdaq: GMAB) has announced the granting of European approval to its development partner, Novartis (NOVN: VX), for Kesimpta (ofatumumab).</p>\n<p>Kesimpta is a targeted B-cell therapy being developed and marketed worldwide by Novartis under a license agreement with Genmab.</p>\n<p>The therapy has shown superior efficacy with a similar safety profile compared with teriflunomide, an oral multiple sclerosis (MS) therapy sold by Sanofi (Euronext: SAN) as Aubagio.</p>\n<p>Uniquely, Kesimpta is the first B-cell therapy that can be self-administered once monthly at home, using a special autoinjector pen.</p>\n<h2>Kesimpta development</h2>\n<p>EU approval for Kesimpta has been granted for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features.</p>\n<p>The regulatory nod was based on data from the Phase III ASCLEPIOS I and II trials, which were published in The New England Journal of Medicine.</p>\n<p>The decision comes more than six months after the US Food and Drug Administration granted approval for the treatment in this indication.</p>\n<p>Novartis hopes that the novel, patient-friendly mode of administration will help it to differentiate the offering from another anti-CD20 antibody on the market, the intravenous therapy Ocrevus (ocrelizumab), from fellow Swiss firm Roche (ROG: SIX).</p>\n<p>With Ocrevus boasting impressive levels of efficacy, Novartis will face stiff competition. Roche&rsquo;s offering - which also has a lower wholesale acquisition cost - is expected by analysts to be the market leader by 2026.</p>\n<p>Commenting on the EU approval, Genmab chief executive Jan van de Winkel said: &ldquo;We are extremely pleased that Kesimpta is now approved in both Europe and in the USA, providing RMS patients with a convenient, efficacious and safe treatment option as demonstrated in the study findings from the ASCLEPIOS trials.&rdquo;</p>\n<p>He added: &ldquo;We are looking forward to the launch of Kesimpta in the various European markets.&rdquo;</p>", "date": "2021-03-30 13:00:00", "meta_title": NaN, "meta_keywords": "Kesimpta, Novartis, approval, therapy, Genmab, multiple, sclerosis, development, European, Self-injectable, antibody, wins, granting, Danish, Europe, cance", "meta_description": "Danish cancer specialist Genmab has announced the granting of European approval to its development partner, Novartis, for Kesimpta (ofatumumab).", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-30 13:00:10", "updated": "2021-03-30 13:41:17", "access": NaN, "url": "https://www.thepharmaletter.com/article/self-injectable-antibody-wins-multiple-sclerosis-nod-in-europe", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "kesimpta_big.jpg", "image2id": "kesimpta_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "CNS Diseases, Musculoskeletal", "topic_tag": "European Medicines Agency, Focus On, Regulation, Research", "geography_tag": "Denmark, Europe, Switzerland", "company_tag": "Genmab, Novartis, Roche", "drug_tag": "Kesimpta, Ocrevus", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-30 13:00:00"}